There are 3162 resources available
2004P - The combination of high levels of serum cytokeratin fragment 21-1 and VI-RADS≧4 has diagnostic and prognostic value in high-stage bladder cancer
Presenter: Shunsuke Ikuma
Session: Poster session 13
2005P - Prediction of response and identification of mechanisms of resistance to neoadjuvant chemotherapy according to molecular subtypes in muscle-invasive bladder carcinoma
Presenter: Alvaro Pinto Marin
Session: Poster session 13
2006P - Prognostic factors in metastatic urothelial cancer (mUC): Developing an accessible model for predicting patient survival
Presenter: Sevinc Balli
Session: Poster session 13
2007P - Similar genetic profile in early and late-stage urothelial tract cancer suggests that early genomic testing bears the potential of timely personalized treatment in clinical trials
Presenter: Dag Rune Stormoen
Session: Poster session 13
2008P - Assessing response durability and survival after second-line pembrolizumab in advanced urothelial carcinoma: A multicenter validation of a risk model
Presenter: Samer Salah
Session: Poster session 13
2010P - Trifunctional anti-EpCAM/CD3 bsAb catumaxomab intravesically for high and intermediate risk non muscle invasive bladder cancer (HMR-NMIBC): Interim analysis of a phase I study
Presenter: Aleksander Antoniewicz
Session: Poster session 13
2011P - Neoadjuvant immunotherapy-driven bladder preservation for muscle-invasive bladder cancer: A multicenter, propensity score-matched cohort study
Presenter: Jiao Hu
Session: Poster session 13
2012P - Role of first-line immunotherapy in urothelial cancer with bone metastases: A national cancer database analysis of 3971 patients
Presenter: Zin Myint
Session: Poster session 13
2013P - First preliminary results of artificial intelligence generated treatment recommendations for urothelial cancer based on multidisciplinary cancer conferences from the KITTU project
Presenter: Gregor Duwe
Session: Poster session 13